Dupixent (Dupilimab) treatment for Atopic Dermatitis is now available

Dupixent, humanized monoclonal antibody, anti-IL-4, anti-IL13, is now available for the treatment of poorly controlled moderate to severe Atopic dermatitis/eczema in patients ages 18 years and older. Studies are under way for patients under 18 years of age.

It is a small injection under the skin every 2 week.

Contact our office for an appointment if you are interested in finally getting her eczema under control.